Anew drug combination shrunk brain tumors in HER2-positive breast cancer patients whose cancer had spread to the brain, showing it is active as a first-line brain metastases treatment. Lapatinib (Tykerb) combined with capecitabine (Xeloda) showed similar efficacy to whole-brain radiotherapy, the ...
Overall, T-DXd appears to be a promising treatment option for patients with HER2+ metastatic breast cancer, especially those with stable or active BM.Here, Nancy Lin, MD, professor of medicine, Harvard Medical School, and medical oncologist, Harvard Cancer In...
The risk of postmenopausal breast cancer was significantly increased for women with MetS (OR = 1.75, 95% CI 1.37-2.22, for three or more MetS components, P for trend for increasing number of components < 0.0001) and the risk was higher at older age (OR = 3.04, 95% CI 1.75-5.29, at...
Advances in Treating HER2+ Breast Cancer With Brain Metastases The Impact of T-DXd in HER2-Positive Breast Cancer Challenges in Treating Brain Metastasis in HER2-Positive Breast Cancer T-DXd Shows Promise in Treating HER2+ Breast Cancer With Brain Me...
Dr. Veronique Desaulniers, DCBREAST CANCER CONQUEROR® I BEST-SELLING AUTHORis dedicated to educating and empowering women with breast cancer how to survive and THRIVE so that they can live a happier and healthier life, while Never Fearing Breast Cance
Ok! (HealthDay)—For patients with early-stage breast cancer with no preexisting metabolic syndrome (MetS), chemotherapy is associated with increased risk of MetS, according to a study published online May 24 inCancer. Ad Christina M. Dieli-Conwright, Ph.D., from the University of Southern ...
Zoledronic acid (ZA) as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells (DTC) in bone marrow (BM) Background: Only a few small studies investigated the association between postmenopausal breast cancer and metabolic syndrome (MetS) as a single entity. Ma.....
Metabolic syndrome (MetS) and most of its components have been previously associated with increased breast cancer risk. We hypothesized that increasing number of MetS components would be positively associated with breast cancer risk. Data were obtained from the Study of Osteoporotic Fractures, a ...
Why don’t breast cancer patients with bone mets get ongoing brain scans? “Brain imaging is typically reserved for cancer patients who exhibit symptoms concerning for brain metastases, such as chronic headaches, vision changes, speech changes, seizures, cognitive concerns, etc.,” says Dr. Stegal...
EP: 1.Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets EP: 2.Clinical Approaches in Treating HER2+ Breast Cancer and Brain Metastases EP: 3.T-DXd and the DESTINY-Breast12 Trial for HER2+ Advanced BC With or Without Brain Mets EP: 4.The Impact of Tr...